LONDON, UK and CAMBRIDGE, Mass. — Beacon Therapeutics Holdings Limited (Beacon Therapeutics or the Company), a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular diseases, today announced a 12-month safety and efficacy update from its Phase 2 DAWN trial...

DURHAM, N.C. — Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, this week presented data from three studies at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Denver, CO. The presentations included 12-month...

BOSTON, Mass. — Day One Biopharmaceuticals, Inc., now part of Servier Group, today announced that it has completed enrollment in the FIREFLY-2 clinical trial, which is evaluating the efficacy, safety and tolerability of tovorafenib vs standard of care chemotherapy in the front-line setting of therapy for patients aged 6 months to 25 years with...